Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

Launched by DOW UNIVERSITY OF HEALTH SCIENCES · Sep 10, 2024

Keywords

ClinConnect Summary

Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department Dow university hospital. Informed consent will be obtained from all the patients.

Demographic details of patients including age, gender, education, occupation and marital status will be obtained. Further each patient will be asked about duration of vitiligo and any systemic medications used by the patients in the last 6 months will be recorded.

Body Surface Area will be calculated and patients with \> 5% of BSA will be included in the study.

Subjects will be rand...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age 18 years and above
• • Patients of both genders (male and female)
• • Diagnosed patients of non-segmental vitiligo involving \> 5% of BSA
• Exclusion Criteria:
• • Pregnant and lactating women
• • Concomitant active infection like tuberculosis
• • Personal history of cutaneous malignancy
• • Use of apremilast in the past 4 weeks
• • Use of phototherapy within 4 weeks before randomization